Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris

Journal of Dermatology

Volumn 34, Issue 7, 2007, Pages 430-434

  Hashizume, Hideo ^a   Ito, Taisuke ^a   Yagi, Hiroaki ^a   Takigawa, Masahiro ^a   Kageyama, Hazuki ^b   Furukawa, Fukiko ^c   Hata, Maki ^d   Shirahama, Shigeho ^e   Tanaka, Masato ^f   Higashishiba, Teruomi ^g   Machida, Hideki ^h   Tsushima, Tomoo ⁱ   Matsushita, Kayo ^j  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Iwata City Hospital   (Japan)

^c Shizuoka Prefectural General Hospital   (Japan)

^d Numazu City Hospital   (Japan)

^e SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^f SHIMADA MUNICIPAL HOSPITAL   (Japan)

^g Shimizu Kousei Hospital   (Japan)

^h Fujinomiya City General Hospital   (Japan)

ⁱ East Medical Center   (Japan)

^j Rosai Hospital   (Japan)

more..

Author keywords

Cyclosporine; Preprandial administration; Psoriasis vulgaris

Indexed keywords

CYCLOSPORIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DYSPNEA; ELECTROLYTE DISTURBANCE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; MICROEMULSION; MULTICENTER STUDY; POSTPRANDIAL STATE; PSORIASIS VULGARIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; EMULSIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PILOT PROJECTS; POSTPRANDIAL PERIOD; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 34250751223     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2007.00305.x     Document Type: Article

References (15)

1. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000 4 : 1 125.
2. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005 53 : S59 69.
3. Berth-Jones J, Henderson CA, Munro CS et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol 1997 136 : 527 530.
4. Ho VC, Griffiths CE, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001 44 : 643 651.
5. Salek MS, Finlay AY, Lewis JJ, Sumner MI. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral). Qual Life Res 2004 13 : 91 95.
6. Griffiths CE, Dubertret L, Ellis CN et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004 150 (Suppl 67 11 23.
7. Umezawa Y, Ozawa A. Cyclosporin therapy based on the TDM (therapeutic drug monitoring) for psoriasis. Clinical Dermatology (Japanese) 2004 58 96 100.
8. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 152 : 861 867.
9. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996 14 : 485 496.
10. Hakkaart-van Roijen L, Verboom P, Redekop WK, Touw KR, Rutten FF. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis. Pharmacoeconomics 2001 19 : 599 608.
11. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999 41 : 581 583.
12. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004 140 : 408 414.
13. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 : 280 284.
14. Opmeer BC, Heydendael VM, De Borgie CA et al. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 2004 140 : 685 690.
15. Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat 2005 16 : 37 42.